{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:04:29Z","timestamp":1761555869676,"version":"build-2065373602"},"reference-count":23,"publisher":"Scientific Scholar","content-domain":{"domain":["nmji.in"],"crossmark-restriction":true},"short-container-title":["NMJI"],"abstract":"\n Background<\/jats:title>\n We aimed to evaluate the efficacy and safety of anticoagulant therapy, especially direct oral anticoagulant (DOAC) therapy, for primary prevention of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism (PE), in non-bedridden cancer patients undergoing chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n English and Chinese literature published from the inception of the databases up to December 2022 was extracted from five databases: PubMed, Embase, MEDLINE, Wanfang Medical and CNKI. Statistical analysis was done using Stata\/SE 16.0 software.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Eight randomized controlled trials were included in this meta-analysis. The results showed that DOACs were effective in preventing symptomatic PE in cancer patients (Log risk ratio [RR]=\u20130.89, 95% confidence interval [CI]: \u20131.73, \u20130.05). Moreover, compared to the control group, DOACs did not increase the risk of major bleeding (Log RR 0.55, 95% CI \u20130.20, 1.30).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The meta-analysis indicates that in cancer patients, DOACs have a significant effect on the prevention of PE, with good safety profile and no increased risk of major bleeding.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/nmji_878_2023","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:59:51Z","timestamp":1761555591000},"page":"268-274","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of anticoagulants on preventing venous thromboembolism in cancer patients: A systematic review and meta-analysis"],"prefix":"10.25259","volume":"38","author":[{"given":"JINCHENG","family":"MA","sequence":"first","affiliation":[{"name":"Department of Intensive Care Unit, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310022, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIAOYAN","family":"KE","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310022, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DAN","family":"ZHU","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Unit, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310022, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"10.25259\/NMJI_878_2023\/ref-1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M22-1258","article-title":"Anticoagulant therapy for cancer-associated thrombosis\/: A cost-effectiveness analysis","volume":"176","author":"Gulati","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.25259\/NMJI_878_2023\/ref-2","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0049-3848(20)30392-3","article-title":"Cancer-associated thrombosis in pediatric patients","volume":"191","author":"Barg","year":"2020","journal-title":"Thromb Res"},{"key":"10.25259\/NMJI_878_2023\/ref-3","doi-asserted-by":"publisher","first-page":"15770","DOI":"10.3390\/ijms232415770","article-title":"Antithrombin activity and association with risk of thrombosis and mortality in patients with cancer","volume":"23","author":"Englisch","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.25259\/NMJI_878_2023\/ref-4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","article-title":"Mechanisms and biomarkers of cancer-associated thrombosis","volume":"225","author":"Kim","year":"2020","journal-title":"Transl Res J Lab Clin Med"},{"key":"10.25259\/NMJI_878_2023\/ref-5","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1182\/blood.2019001388","article-title":"Platelets and cancer-associated thrombosis: Focusing on the platelet activation receptor CLEC-2 and podoplanin","volume":"134","author":"Suzuki-Inoue","year":"2019","journal-title":"Blood"},{"key":"10.25259\/NMJI_878_2023\/ref-6","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.25259\/NMJI_878_2023\/ref-7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.25259\/NMJI_878_2023\/ref-8","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.3390\/curroncol28060453","article-title":"Treatment algorithm in cancer-associated thrombosis: Updated Canadian expert consensus","volume":"28","author":"Carrier","year":"2021","journal-title":"Curr Oncol Tor Ont"},{"key":"10.25259\/NMJI_878_2023\/ref-9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1055\/s-0039-1693472","article-title":"Cancer-associated thrombosis: A two-way street","volume":"45","author":"9 Sharma","year":"2019","journal-title":"Semin ThrombHemost"},{"key":"10.25259\/NMJI_878_2023\/ref-10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/bjh.18276","article-title":"Unanswered questions in cancer-associated thrombosis","volume":"198","author":"Sanfilippo","year":"2022","journal-title":"Br J Haematol"},{"key":"10.25259\/NMJI_878_2023\/ref-11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.25259\/NMJI_878_2023\/ref-12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/0197-2456(93)90214-X","article-title":"Efficacy of double-blinding in a randomized controlled trial (RCT) of low dose warfarin to prevent thromboembolic disease in patients with metastatic breast cancer","volume":"14","author":"Levine","year":"1994","journal-title":"Control Clin Trials"},{"key":"10.25259\/NMJI_878_2023\/ref-13","doi-asserted-by":"publisher","first-page":"e20514","DOI":"10.1200\/jco.2009.27.15_suppl.e20514","article-title":"A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer","volume":"27","author":"Levine","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.25259\/NMJI_878_2023\/ref-14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1200\/JCO.1989.7.8.993","article-title":"A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the cancer and leukemia group B","volume":"7","author":"Chahinian","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.25259\/NMJI_878_2023\/ref-15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_878_2023\/ref-16","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1055\/s-0040-1712143","article-title":"Assessing full benefit of rivaroxaban prophylaxis in high-risk ambulatory patients with cancer: Thromboembolic events in the randomized CASSINI trial","volume":"4","author":"Khorana","year":"2019","journal-title":"TH Open"},{"key":"10.25259\/NMJI_878_2023\/ref-17","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F","article-title":"Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA cooperative study #75","volume":"53","author":"Zacharski","year":"1981","journal-title":"Cancer"},{"key":"10.25259\/NMJI_878_2023\/ref-18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.V114.22.492.492","article-title":"A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens","volume":"114","author":"Palumbo","year":"2009","journal-title":"Blood"},{"key":"10.25259\/NMJI_878_2023\/ref-19","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1200\/JCO.1997.15.11.3378","article-title":"Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A cancer and leukemia group B study","volume":"15","author":"Maurer","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.25259\/NMJI_878_2023\/ref-20","doi-asserted-by":"publisher","first-page":"e12681","DOI":"10.1016\/j.heliyon.2022.e12681","article-title":"Machine learning predicts cancer-associated venous thromboembolism using clinically available variables in gastric cancer patients","volume":"9","author":"Xu","year":"2023","journal-title":"Heliyon"},{"key":"10.25259\/NMJI_878_2023\/ref-21","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"10.25259\/NMJI_878_2023\/ref-22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"McBane Ii","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.25259\/NMJI_878_2023\/ref-23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nmji.in\/the-effect-of-anticoagulants-on-preventing-venous-thromboembolism-in-cancer-patients-a-systematic-review-and-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nmji.in\/the-effect-of-anticoagulants-on-preventing-venous-thromboembolism-in-cancer-patients-a-systematic-review-and-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:59:52Z","timestamp":1761555592000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/the-effect-of-anticoagulants-on-preventing-venous-thromboembolism-in-cancer-patients-a-systematic-review-and-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":23,"alternative-id":["10.25259\/NMJI_878_2023"],"URL":"https:\/\/doi.org\/10.25259\/nmji_878_2023","relation":{},"ISSN":["2583-150X","0970-258X"],"issn-type":[{"type":"electronic","value":"2583-150X"},{"type":"print","value":"0970-258X"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"article-number":"268"}}